Jump to main content
Jump to site search

Issue 41, 2018
Previous Article Next Article

Engineering and evaluation of amyloid assemblies as a nanovaccine against the Chikungunya virus

Author affiliations

Abstract

The design of nanoparticles exposing a high density of antigens constitutes a promising strategy to address safety concerns of conventional life-attenuated vaccines as well as to increase the immunogenicity of subunit vaccines. In this study, we developed a fully synthetic nanovaccine based on an amyloid peptide sequence with high self-assembling properties. The immunogenic epitope E2EP3 from the E2 glycoprotein of the Chikungunya virus was used to evaluate the potential of a 10-mer peptide derived from an endogenous amyloidogenic polypeptide as a novel vaccine platform. Chimeric peptides, comprising the peptide antigen attached to the amyloid core by a short flexible linker, were prepared by solid phase synthesis. As observed using atomic force microscopy, these polypeptides self-assembled into linear and unbranched fibrils with a diameter ranging from 6 to 8 nm. A quaternary conformation rich in cross-β-sheets characterized these assemblies, as demonstrated by circular dichroism spectroscopy and thioflavin T fluorescence. ELISA assays and transmission electronic microscopy of immunogold labeled-fibrils revealed a high density of the Chikungunya virus E2 glycoprotein derived epitope exposed on the fibril surface. These amyloid fibrils were cytocompatible and were efficiently uptaken by macrophages. Mice immunization revealed a robust IgG response against the E2EP3 epitope, which was dependent on self-assembly and did not require co-injection of the Alhydrogel adjuvant. These results indicate that cross-β-sheet amyloid assemblies constitute suitable synthetic self-adjuvanted assemblies to anchor antigenic determinants and to increase the immunogenicity of peptide epitopes.

Graphical abstract: Engineering and evaluation of amyloid assemblies as a nanovaccine against the Chikungunya virus

Back to tab navigation

Supplementary files

Publication details

The article was received on 23 Jul 2018, accepted on 26 Sep 2018 and first published on 26 Sep 2018


Article type: Paper
DOI: 10.1039/C8NR05948A
Citation: Nanoscale, 2018,10, 19547-19556
  •   Request permissions

    Engineering and evaluation of amyloid assemblies as a nanovaccine against the Chikungunya virus

    M. Babych, G. Bertheau-Mailhot, X. Zottig, J. Dion, L. Gauthier, D. Archambault and S. Bourgault, Nanoscale, 2018, 10, 19547
    DOI: 10.1039/C8NR05948A

Search articles by author

Spotlight

Advertisements